Treatment Patterns of ALK+ Non-Small Cell Lung Cancer in Western Europe
نویسندگان
چکیده
منابع مشابه
Future of ALK inhibition in non-small-cell lung cancer.
Progress in defi ning molecular targets of oncogenesis and drugs to inhibit cancer growth in specifi c populations has led to augmented outcomes for patients and new expectations in the development of treatments. The EML4–ALK fusion protein was identifi ed in patients with non-small-cell lung cancer (NSCLC) in 2007. Rearrangements in the ALK gene lead to constitutive signalling, triggering tran...
متن کاملALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ALK has been associated with other types of cancers, including non-small-cell ...
متن کاملCeritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
Authors' disclosures of potential conflicts of interest are found at the end of this article. A ccording to the American Cancer Society (ACS), lung cancer is the second most common diagnosis in the world and is the leading cause of death from malignancy in both men and women (ACS, 2014). Lung cancer accounts for 13% of new diagnoses and 27% of deaths from malig-nancy. The ACS (2014) estimated t...
متن کاملALK inhibitors and advanced non-small cell lung cancer (review).
Treatment of unselected patients with advanced non-small cell lung cancer (NSCLC) receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. Histology and molecular analyses are the cornerstone in the initial diagnosis of NSCLC and are key determinants to address the appropriate strategy of treatment. In non-squamous histology the combination of cisplatin plu...
متن کاملProfile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), a subset of epithelial lung cancers that are generally insensitive to chemotherapy. An estimated 3%-7% of NSCLC patients harbor tum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2016
ISSN: 1098-3015
DOI: 10.1016/j.jval.2016.09.2387